Investigated for use/treatment in solid tumors, lung cancer, ovarian cancer, and prostate cancer.
- Mechanism
- Curator reviewed
ASA404 (DMXAA) is a small-molecule vascular disrupting agent which targets the blood vessels that nourish tumours. The proposed mechanism of action for ASA404 is directly increasing permeability of the tumor's endothelial cells. Vasoactive mediators such as tumor necrosis factor (TNF) may also be implicated. Increased permeability of tumor cell vasculature may allow increased permeation of anticancer treatments such as cytotoxic drugs, antibodies, drug conjugates and gene therapy.
- Primary indication
- Investigated for use/treatment in solid tumors, lung cancer, ovarian cancer, and prostate cancer.Curator reviewed
- Formula / weight
- C17H14O4 · 282.2907 g/mol (avg)
- Also known as
- 5,6-MeXAA · Dimethyloxoxanthene acetic acid · DMXAA
- Code names
- AS-1404 · ASA-404 · NSC-640488
Resolves to
XGOYIMQSIKSOBS-UHFFFAOYSA-NSMILESCC1=C(C)C2=C(C=C1)C(=O)C1=CC=CC(CC(O)=O)=C1O2What you can answer from here — as of August 30, 2026
Which drugs share a target with Vadimezan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account